AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone386-462-6800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$83.94 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date8/7/2019 (Estimated)
OptionableOptionable
AxoGen (NASDAQ:AXGN) Frequently Asked Questions
What is AxoGen's stock symbol?
AxoGen trades on the NASDAQ under the ticker symbol "AXGN."
How were AxoGen's earnings last quarter?
AxoGen, Inc (NASDAQ:AXGN) released its quarterly earnings data on Wednesday, May, 8th. The medical equipment provider reported ($0.21) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.20) by $0.01. The medical equipment provider had revenue of $23.30 million for the quarter, compared to analysts' expectations of $22.33 million. AxoGen had a negative net margin of 29.19% and a negative return on equity of 15.58%. AxoGen's revenue for the quarter was up 34.7% compared to the same quarter last year. During the same period last year, the company earned ($0.11) earnings per share. View AxoGen's Earnings History.
When is AxoGen's next earnings date?
What guidance has AxoGen issued on next quarter's earnings?
AxoGen updated its FY 2019 earnings guidance on Tuesday, February, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $109-114 million, compared to the consensus revenue estimate of $113.63 million.
What price target have analysts set for AXGN?
3 analysts have issued twelve-month price targets for AxoGen's stock. Their forecasts range from $29.00 to $55.00. On average, they anticipate AxoGen's share price to reach $38.00 in the next twelve months. This suggests a possible upside of 78.2% from the stock's current price. View Analyst Price Targets for AxoGen.
What is the consensus analysts' recommendation for AxoGen?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AxoGen.
What are Wall Street analysts saying about AxoGen stock?
Here are some recent quotes from research analysts about AxoGen stock:
- 1. BTIG Research analysts commented, "Raise PT to $29 We reiterate our Buy rating and raise our price target to $29 (from $28) following 1Q19 results. 1Q19 results beat both BTIG and Consensus est. with rev. of $23.3M (+34.9% Y/Y) coming in ahead of (~29% implied). Expenses were elevated as one-timers, increasing sales reps, and costs associated with RECON stepped up, but mgmt. expects these costs to moderate through the year. When we upgraded AXGN intra-quarter (here), the crux of our thesis was that improved stability and hiring trends in the sales force following the leadership transition would lead to more consistent execution and allow AXGN to return to improved growth. Thus far, results are playing out as we surmised but we acknowledge it’s still early in the year." (5/10/2019)
- 2. Cantor Fitzgerald analysts commented, "We think AXGN is one of the most compelling growth stories in medtech, with what we believe is sustainable top-line growth of north of 30% for the next two years. We expect utilization to accelerate as favorable clinical and economic data builds and increases surgeon awareness. We would also expect the company to continue to pursue additional market opportunities, as the technology is applicable to nerves across the body. Valuation Summary We value AXGN using a 6x EV/Sales multiple on our 2020 sales estimate to arrive at our 12-month price target of $26." (1/18/2019)
Has AxoGen been receiving favorable news coverage?
News stories about AXGN stock have trended negative this week, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. AxoGen earned a coverage optimism score of -2.0 on InfoTrie's scale. They also assigned media stories about the medical equipment provider a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an effect on the stock's share price in the near future.
Who are some of AxoGen's key competitors?
Some companies that are related to AxoGen include CONMED (CNMD), NxStage Medical (NXTM), Natus Medical (BABY), Viewray (VRAY), TransMedics Group (TMDX), BioLife Solutions (BLFS), Semler Scientific (SMLR), Rockwell Medical (RMTI), Cutera (CUTR), Zynex (ZYXI), Stereotaxis (STXS), BioSig Technologies (BSGM), Fonar (FONR), Edap Tms (EDAP) and Second Sight Medical Products (EYES).
What other stocks do shareholders of AxoGen own?
Who are AxoGen's key executives?
AxoGen's management team includes the folowing people:
- Ms. Karen Zaderej, Chairman, Pres & CEO (Age 57)
- Mr. Peter J. Mariani, Chief Financial Officer (Age 55)
- Mr. Gregory G. Freitag Esq., J.D., CPA, Gen. Counsel & Director (Age 57)
- Mr. Michael Donovan, VP of Operations (Age 54)
- Ms. Kaila Paige Krum, VP of Investor Relations & Corp. Devel.
Who are AxoGen's major shareholders?
AxoGen's stock is owned by many different of retail and institutional investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (9.29%), BlackRock Inc. (6.33%), Opaleye Management Inc. (2.82%), Baillie Gifford & Co. (2.52%), Eagle Asset Management Inc. (1.95%) and Peregrine Capital Management LLC (1.21%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, David K Hansen, Gregory Gene Freitag, Guido J Neels, Jamie Mark Grooms, Karen L Zaderej, Robert James Rudelius and Shawn F Mccarrey. View Institutional Ownership Trends for AxoGen.
Which institutional investors are selling AxoGen stock?
AXGN stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Wells Fargo & Company MN, Morgan Stanley, Opaleye Management Inc., Eagle Asset Management Inc., BlackRock Inc., FMR LLC and SG Americas Securities LLC. Company insiders that have sold AxoGen company stock in the last year include David K Hansen, Gregory Gene Freitag and Karen L Zaderej. View Insider Buying and Selling for AxoGen.
Which institutional investors are buying AxoGen stock?
AXGN stock was bought by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Frontier Capital Management Co. LLC, Baillie Gifford & Co., Schonfeld Strategic Advisors LLC, Man Group plc, Penn Capital Management Co. Inc., Granite Investment Partners LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for AxoGen.
How do I buy shares of AxoGen?
Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AxoGen's stock price today?
One share of AXGN stock can currently be purchased for approximately $21.33.
How big of a company is AxoGen?
AxoGen has a market capitalization of $830.70 million and generates $83.94 million in revenue each year. The medical equipment provider earns $-22,400,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.
What is AxoGen's official website?
How can I contact AxoGen?
AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]
MarketBeat Community Rating for AxoGen (NASDAQ AXGN)
MarketBeat's community ratings are surveys of what our community members think about AxoGen and other stocks. Vote "Outperform" if you believe AXGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
